[go: up one dir, main page]

TN2018000137A1 - Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection - Google Patents

Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection

Info

Publication number
TN2018000137A1
TN2018000137A1 TNP/2018/000137A TN2018000137A TN2018000137A1 TN 2018000137 A1 TN2018000137 A1 TN 2018000137A1 TN 2018000137 A TN2018000137 A TN 2018000137A TN 2018000137 A1 TN2018000137 A1 TN 2018000137A1
Authority
TN
Tunisia
Prior art keywords
trispecific
binding proteins
prevention
treatment
hiv infection
Prior art date
Application number
TNP/2018/000137A
Inventor
Mangaiarkarasi Asokan
Christian Beil
Jochen Beninga
Mark Connors
Nicole Doria-Rose
Jinghe Huang
Richard Koup
Jochen Kruip
Young Kwon
Peter Kwong
Christian Lange
Wulf Leuschner
John Mascola
Gary Nabel
Amarendra Pegu
Huawei Qiu
Ercole Rao
Ronnie Wei
Ling Xu
Zhi-Yong Yang
Tongqing Zhou
Original Assignee
Sanofi Sa
The Usa As Represented By The Sec Dep Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, The Usa As Represented By The Sec Dep Of Health And Human Services filed Critical Sanofi Sa
Priority claimed from PCT/US2016/058540 external-priority patent/WO2017074878A1/en
Publication of TN2018000137A1 publication Critical patent/TN2018000137A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided herein are compositions comprising trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins or one or more T-cell receptors, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. Also provided herein are methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins for the treatment and/or prevention of HIV/ AIDS.
TNP/2018/000137A 2015-10-25 2016-10-24 Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection TN2018000137A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562246113P 2015-10-25 2015-10-25
EP16305211 2016-02-24
US201662322029P 2016-04-13 2016-04-13
US201662331169P 2016-05-03 2016-05-03
PCT/US2016/058540 WO2017074878A1 (en) 2015-10-25 2016-10-24 Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection

Publications (1)

Publication Number Publication Date
TN2018000137A1 true TN2018000137A1 (en) 2019-10-04

Family

ID=69671420

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP/2018/000137A TN2018000137A1 (en) 2015-10-25 2016-10-24 Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection

Country Status (5)

Country Link
DK (1) DK3365366T3 (en)
EC (1) ECSP18039758A (en)
LT (1) LT3365366T (en)
SG (1) SG10202003467RA (en)
TN (1) TN2018000137A1 (en)

Also Published As

Publication number Publication date
SG10202003467RA (en) 2020-05-28
ECSP18039758A (en) 2018-10-31
LT3365366T (en) 2021-11-25
DK3365366T3 (en) 2021-10-18

Similar Documents

Publication Publication Date Title
PH12018500873A1 (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
PH12018502182A1 (en) Trispecific and/or trivalent binding proteins
WO2016207273A3 (en) Multispecific antigen binding proteins
EP3882270A3 (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
MX2022013524A (en) Human immunodeficiency virus neutralizing antibodies.
MY208876A (en) Trispecific binding proteins, methods, and uses thereof
PH12014501818A1 (en) Pseudomonas aeruginosa pcrv binding single variable domain antibodies
MX2021000387A (en) Fc binding fragments comprising cd137 antigne binding side.
MX2021013417A (en) Clec12a-binding polypeptides and uses thereof.
WO2018069871A3 (en) Anti-kras binding proteins
MX2023004804A (en) Trispecific and/or trivalent binding proteins.
PH12017501914A1 (en) Polypeptides targeting hiv fusion
PH12021500042A1 (en) Trispecific and/or trivalent binding proteins using the cross-over-dual-variable domain (codv) format for treatment of hiv infection
TN2018000137A1 (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
TN2018000345A1 (en) Trispecific and/or trivalent binding proteins
WO2017075484A3 (en) Highly potent antibodies binding to death receptor 4 and death receptor 5
EA202191078A3 (en) TRISSPECIFIC AND / OR TRIVALENT BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION
EP3890776A4 (en) Recombinant hiv env polypeptides and their uses
EA202090727A1 (en) ANTIBODY OPTIONS
MX2021011854A (en) JOINT ANTINEOPLASTIC TREATMENT.
HK40063187A (en) Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
HK40068659A (en) Il1rap binding proteins
HK40044124A (en) Trispecific antigen binding proteins
MX366923B (en) Dual variable region antibody-like binding proteins having cross-over binding region orientation.
HK1243092A1 (en) Fn14-binding proteins and uses thereof